PhRMA Kicks Off New Agenda, Including Endorsement of Drug Pricing Reforms
National lobbying group PhRMA introduced a new agenda this week with a pointed message at the White House: pharma has [...]
ICER Publishes Methodology on Evaluating Unsupported Drug Price Increases
ICER has released a protocol detailing how it analyses UPIs (Unsupported Price Increases) for prescription drugs in the United States. [...]
ISPOR Europe’s Issue Panels and Workshops Open for Abstract Submissions
ISPOR Europe 2021 will take place virtually at the beginning of December. Its Issue Panels and Workshop sessions are currently [...]
How Will Coming HHS Interoperability Mandate Affect Payer’s Market Access?
A new interoperability mandate will take effect in July 2021 and is expected to shift how data can be shared. [...]
Understanding the Expanded Role of the Medical Affairs Professional
Medical affairs professionals are responsible for representing their organizations and clearly conveying important information. In some cases, they can also [...]
ICER to Consider Aetion RWE in Revision of Hereditary Angioedema Therapy Report
ICER (the Institute for Clinical and Economic Review) has announced its decision to utilize RWE (real world evidence) data in [...]
The Patient Side of Successful Drug Development
More and more, patient opinions are being considered when it comes to designing effective therapeutics and testing their efficacy. A [...]
ICER Announces Final Evidence Report for FibroGen’s Roxadustat, Uncertainties Linger
ICER has released a final evidence report for roxadustat, along with policy recommendations. Cardiovascular risks were one of the concerns [...]
Whitepaper on Field Medical Engagement During the COVID-19 Pandemic
Following the annual MAPS (Medical Affairs Professional Society) meeting, select members formed a group to discuss key challenges related to [...]
Virtual ISPOR 2021 Prerelease Session on HTAs in Clinical Trial Design
ISPOR will take place virtually from May 17th to 20th. Prerelease sessions will be available beginning on April 21st and [...]
Medical Affairs Podcast on Corporate Alliance Management
MAPS (Medical Affairs Professional Society) is offering an on-demand podcast featuring insight from professionals with experience as medical strategists, as [...]
Webinar on New Performance Metric for Medical Affairs: Share of Scientific Voice
MAPS (Medical Affairs Professional Society) is offering a webinar discussing SoSV (Share of Scientific Voice), a single metric used to [...]
Considerations and Challenges for RWD Include Data Matching and Security
HealthVerity discusses several challenges when it comes to using deidentified patient data. Although using patient information can provide unique insight, [...]
ICER To Review Hypertrophic Cardiomyopathy Drug
ICER has announced its intention to review mavacamten, a drug for use in hypertrophic cardiomyopathy. The Draft Scoping Document is [...]
MAPS Mentorship Program Seeking Medical Affairs Mentors and Mentees
MAPS (Medical Affairs Professional Society) is offering a second round of mentorship for 2021 following a successful first round. This [...]
AMCP Offers Two Virtual Corporate Training Events to Enhance Knowledge of Medicare and PIE Strategies
The AMCP (Academy of Managed Care Pharmacy) will offer two virtual events designed to address knowledge gaps for leaders in [...]
Thomas Jefferson University Offers Health Data Science Program
The Jefferson College of Population Health (JCPH) offers a program in Health Data Science. It also offers a short webinar [...]
Healthcare Spending in Massachusetts Increases, Drug Spending Largest Source of Growth
Massachusetts healthcare spending increased for the second year. Pharmacy services, hospital inpatient, hospital outpatient, and physician services all increased in [...]
Using Supplier Data Effectively to Improve Organization Efficiency
Supplier data, including information related to purchasing, sourcing, and contracts, can be useful in the right circumstances, but often leads [...]
AMWA, EMWA, and ISMPP Joint Statement Includes Stakeholder Checklist
The AMWA (American Medical Writers Association), the EMWA (European Medical Writers Association), and the ISMPP (International Society for Medical Publication [...]
IQVIA Announces New Virtual Series on Making the Most of RWE
IQVIA has announced a four-session webcast series on the use of RWE (real world evidence) in drug development leading to [...]
Three Medical Writing Associations Issue Joint Statement on State of Peer Review Process, Highlight Rushed COVID-19 Publications
In a joint statement by the AMWA (American Medical Writers Association), the EMWA (European Medical Writers Association), and the ISMPP [...]
ICER Releases Evidence Report on Lupus Nephritis Drugs
ICER has published a new evidence report on two drugs for use in lupus nephritis patients. FDA-approved voclosporin and belimumab [...]
Blue Shield of California Expands Network, Seeks to Improve Access to COVID-19 Vaccine
Blue Shield of California has expanded its network coverage to include 1200 COVID-19 vaccination sites. This move is expected to [...]
New PRA Toolkit Helps Researchers Identify Risks in Clinical Trials
Researchers of rare and orphan diseases face unique challenges when it comes to drug development. Enrolling in a clinical trial [...]